Orio Therapeutics SA

The start-up is based on a patented technology developed by the two co-founders at Monash University, Australia, with which they have negotiated a license agreement with an option to secure exclusive rights. The co-founders have developed a drug-delivery technology based on protein engineering. They have shown the efficacy of their platform in animal models of skin, bone, skeletal muscle, and cardiac muscle regeneration. The technology can be applied to virtually any protein therapeutic requiring a local action and the team will initially focus its efforts on an application in acute myocardial infarct patients. The co-founders are now seeking investments to conduct pre-clinical trials with the goal to enter clinical trials in 2025.